13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674712
Total reported value
$1.1B
$1.1B
43 檔
66.1%
At the close of Q3 2024, Vivo Capital, LLC disclosed equity holdings valued at approximately $1.1B, spread across 43 reported holdings.
Vivo Capital, LLC executed strategic sector rebalancing during Q3 2024, establishing 6 new positions while fully exiting 5 holdings and trimming 8 positions.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, GERN, HRMY) accounted for 66.1% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 26.29% | -0.82% | EXIT | |
| 2 | GERN | Geron CORP | Stock-Other | 10.23% | -0.06% | — | |
| 3 | HRMY | Harmony Biosciences Holdings | Stock-Other | 8.63% | — | — | |
| 4 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 8.45% | — | — | |
| 5 | SVA | Sinovac Biotech Ltd. | Stock-Other | 6.32% | +0.32% | — | |
| 6 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 4.76% | -5.85% | EXIT | |
| 7 | TIL | Instil Bio Inc | Stock-Other | 3.48% | +0.01% | — | |
| 8 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.31% | +0.81% | -31.81% | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.16% | -0.27% | EXIT | |
| 10 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.91% | — | — | |
| 11 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.66% | — | — | |
| 12 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.66% | — | — | |
| 13 | ERAS | Erasca Inc | Stock-Other | 1.53% | -9.44% | — | |
| 14 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.49% | -0.06% | -19.63% | |
| 15 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.41% | — | -33.33% | |
| 16 | TRML | Tourmaline Bio Inc | Stock-Other | 1.26% | — | — | |
| 17 | RZLT | Rezolute Inc | Stock-Other | 1.12% | — | — | |
| 18 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.08% | -0.12% | +0.64% | |
| 19 | SERA | Sera Prognostics Inc-a | Stock-Other | 1.07% | -0.01% | — | |
| 20 | COGT | Cogent Biosciences Inc | Stock-Other | 1.00% | -1.35% | EXIT | |
| 21 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.96% | — | — | |
| 22 | CMPS | Compass Pathways PLC | Stock-Other | 0.84% | -0.09% | EXIT | |
| 23 | CELC | Celcuity Inc | Stock-Other | 0.75% | — | — | |
| 24 | DCTH | Delcath Systems Inc | Stock-Other | 0.75% | — | -40.18% | |
| 25 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.65% | +0.42% | — | |
| 26 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.65% | — | — | |
| 27 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.61% | +0.07% | -4.40% | |
| 28 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.54% | -2.65% | — | |
| 29 | IOBTQ | Io Biotech Inc | Stock-Other | 0.54% | — | — | |
| 30 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.48% | — | — | |
| 31 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.45% | +3.63% | — | |
| 32 | VSTM | Verastem Inc | Stock-Other | 0.38% | — | — | |
| 33 | ✓ | Engene Holdings Inc | Stock-Other | 0.37% | — | — | |
| 34 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.28% | — | — | |
| 35 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.19% | — | — | |
| 36 | ALLKGUSD | Allakos Inc | Stock-Other | 0.16% | — | -1.07% | |
| 37 | ✓ | Stock-Other | 0.15% | — | +28.82% | ||
| 38 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.10% | — | — | |
| 39 | CDXS | Codexis Inc | Stock-Other | 0.10% | — | — | |
| 40 | ✓ | Dbv Technologies S A | Stock-Other | 0.08% | — | — | |
| 41 | QTTB | Q32 Bio Inc | Stock-Other | 0.08% | — | — | |
| 42 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.06% | +3.04% | — | |
| 43 | DTIL | Precision Biosciences Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +3.7% | — | Unchanged |
| 2 | ✓ | Avadel Pharmaceuticals PLC ADR | +2.9% | NEW | New buy |
| 3 | TIL | Instil Bio Inc | +2.9% | — | Unchanged |
| 4 | ZBIO | Zenas Biopharma Inc | +1.7% | NEW | New buy |
| 5 | HRMY | Harmony Biosciences Holdings | +1.4% | — | Unchanged |
| 6 | VRDN | Viridian Therapeutics Inc | +1.1% | — | Unchanged |
| 7 | 430 | Terns Pharmaceuticals Inc | +0.9% | +11.53% | Add |
| 8 | CRVS | Corvus Pharmaceuticals Inc | +0.7% | NEW | New buy |
| 9 | TRML | Tourmaline Bio Inc | +0.6% | — | Unchanged |
| 10 | TRVI | Trevi Therapeutics Inc | +0.5% | NEW | New buy |
| 11 | AVU0 | Adverum Biotechnologies Inc | +0.4% | — | Unchanged |
| 12 | ORIC | Oric Pharmaceuticals Inc | +0.3% | +0.64% | Add |
| 13 | ABEO | Abeona Therapeutics Inc | +0.2% | — | Unchanged |
| 14 | CMPX | Compass Therapeutics Inc | +0.2% | — | Unchanged |
| 15 | SERA | Sera Prognostics Inc-a | +0.2% | — | Unchanged |
| 16 | ALGS | Aligos Therapeutics Inc | +0.1% | NEW | New buy |
| 17 | ERAS | Erasca Inc | +0.1% | — | Unchanged |
| 18 | TENX | Tenax Therapeutics Inc | +0.1% | NEW | New buy |
| 19 | QTTB | Q32 Bio Inc | +0.1% | — | Unchanged |
| 20 | RZLT | Rezolute Inc | 0% | — | Unchanged |
| 21 | DTIL | Precision Biosciences Inc | — | — | Unchanged |
| 22 | ✓ | 0% | +28.82% | Add | |
| 23 | CDXS | Codexis Inc | 0% | — | Unchanged |
| 24 | ✓ | Dbv Technologies S A | 0% | — | Unchanged |
| 25 | VSTM | Verastem Inc | 0% | — | Unchanged |
| 26 | BOLT1EUR | Bolt Biotherapeutics Inc | -0.1% | — | Unchanged |
| 27 | CMPS | Compass Pathways PLC | -0.1% | — | Unchanged |
| 28 | WHWK | Whitehawk Therapeutics Inc | -0.1% | EXIT | Sold out |
| 29 | ✓ | Aligos Therapeutics Inc | -0.1% | EXIT | Sold out |
| 30 | ALLKGUSD | Allakos Inc | -0.1% | -1.07% | Trim |
| 31 | IOBTQ | Io Biotech Inc | -0.1% | — | Unchanged |
| 32 | RGLS | Regulus Therapeutics Inc | -0.2% | — | Unchanged |
| 33 | CELC | Celcuity Inc | -0.2% | — | Unchanged |
| 34 | ✓ | Engene Holdings Inc | -0.2% | — | Unchanged |
| 35 | SLN | Silence Therapeutics Plc-adr | -0.3% | — | Unchanged |
| 36 | OLMA | Olema Pharmaceuticals Inc | -0.4% | -19.63% | Trim |
| 37 | CRBP | Corbus Pharmaceuticals Holdi | -0.4% | — | Unchanged |
| 38 | GERN | Geron CORP | -0.4% | — | Unchanged |
| 39 | DCTH | Delcath Systems Inc | -0.5% | -40.18% | Trim |
| 40 | CATBUSD | Astria Therapeutics Inc | -0.6% | -33.33% | Trim |
| 41 | SVA | Sinovac Biotech Ltd. | -0.7% | — | Unchanged |
| 42 | COGT | Cogent Biosciences Inc | -0.8% | -50.00% | Trim |
| 43 | ZLAB | Zai Lab Ltd-adr | -0.9% | EXIT | Sold out |
| 44 | SLNOEUR | Soleno Therapeutics Inc | -1.3% | -14.01% | Trim |
| 45 | TARS | Tarsus Pharmaceuticals Inc | -1.4% | EXIT | Sold out |
| 46 | ALXO | Alx Oncology Holdings Inc | -1.7% | -4.40% | Trim |
| 47 | DYN | Dyne Therapeutics Inc | -2% | -31.81% | Trim |
| 48 | ✓ | Avadel Pharmaceuticals PLC ADR | -5.2% | EXIT | Sold out |
According to official SEC Form 13F filings, Vivo Capital, LLC reported a total U.S. public equity portfolio value of $1.1B across 43 disclosed positions in Q3 2024.
During Q3 2024, Vivo Capital, LLC's top holdings by market value included SLNOEUR (26.3%)、GERN (10.2%)、HRMY (8.6%). The largest single position, SLNOEUR, represented 26.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
Avadel Pharmaceuticals PLC ADR
市值: $35.2M
Top Position Liquidated / Trimmed
Avadel Pharmaceuticals PLC ADR
前期市值: $55.8M
In Q3 2024, Vivo Capital, LLC made 22 total portfolio adjustments, initiating 6 new buys, adding to 3 positions, trimming 8 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.